New Phase 1/2 Study Data for ALXN1210 as a Potential Future Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Be Presented at American Society of Hematology (ASH) Meeting Data […]
April 26, 2017 7:12 AM EDTInitial Data from Global Phase 2 Program Expected Mid-2017 CAMBRIDGE, Mass.–(BUSINESS WIRE)– Ra Pharmaceuticals, Inc. (NASDAQ: RARX) today announced that it has initiated dosing in the […]
The All Party Parliamentary Group (APPG) on Rare, Genetic and Undiagnosed Conditions published a report yesterday looking at the implementation of the UK Strategy for Rare Diseases in England. The […]
In this issue of Blood, Harder et al demonstrate that breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab is due to strong activation of the complement cascade, leading to […]
Achillion slumps 33% on potential safety issue with PNH candidate ACH-4471 Read Here Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan Read Here Akari Therapeutics […]
